Article citationsMore>>

Kao, S.Y., Ekwueme, D.U., Holman, D.M., Rim, S.H., Thomas, C.C. and Saralya, M. (2022) Economic Burden of Skin Cancer Treatment in the United States: An Analysis of the Medical Expenditure Panel Survey Data, 2012-2018. Cancer Causes & Control, 34, 205-212.
https://doi.org/10.1007/s10552-022-01644-0

has been cited by the following article:

• TITLE: Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)?

  AUTHORS: Bill Elliot Cham

  KEYWORDS: Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Mohs Surgery, Microscopic Molecular-Cellular, Curaderm, Actinic Keratosis, Cosmesis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.15 No.2, February 29, 2024

  ABSTRACT: Non-melanoma skin cancers or keratinocyte cancers such as basal cell carcinoma and squamous cell carcinoma make up approximately 80% and 20% respectively, of skin cancers with the 6 million people that are treated annually in the United States. 1 in 5 Americans and 2 in 3 Australians develop skin cancer by the age of 70 years and in Australia it is the most expensive, amassing $1.5 billion, to treat cancers. Non-melanoma skin cancers are often self-detected and are usually removed by various means in doctors’ surgeries. Mohs micrographic surgery is acclaimed to be the gold standard for the treatment of skin cancer. However, a novel microscopic molecular-cellular non-invasive topical therapy described in this article, challenges the status of Mohs procedure for being the acclaimed gold standard.